分析Na⁺/H⁺交换蛋白1（NHE1）抑制剂对癌基因BRAF野生型（BRAF^WT）和激活型BRAF^V600E突变的胶质母细胞瘤（GBM）细胞生长和侵袭能力的影响。

NHE1抑制剂Cariporide分别处理U251（BRAF^WT）和AM38（BRAF^V600E）GBM细胞系，乙酰甲酯化的2’,7’-双（2-羧乙基）-5（6）-羧荧光素荧光探针处理细胞并采用紫外分光光度计检测细胞在440 nm与490 nm的荧光强度，计算荧光强度比值以反映NHE1的活性，MTT法检测细胞增殖活性，基质胶-Transwell实验检测细胞侵袭能力。

AM38细胞的NHE1活性、增殖和侵袭能力均显著高于U251细胞，差异均有统计学意义（P=0.006、0.010、0.047）；Cariporide处理的U251和AM38细胞的NHE1活性、增殖和侵袭能力均显著低于溶剂二甲基亚砜处理的U251和AM38细胞，差异均有统计学意义（U251：P=0.012、0.023、0.044；AM38：P=0.006、0.001、0.038）。

采用Cariporide阻断NHE1活性可有效抑制BRAF^WT和BRAF^V600E突变型GBM细胞的增殖和侵袭。

To analyze the effection of Na⁺/H⁺ exchanger 1(NHE1) on proliferation and invasion abilities of oncogene BRAF wild type(BRAF^WT) and BRAF^V600E mutation type glioblastoma (GBM) cells.

The U251 (BRAF^WT) and AM38 (BRAF^V600E) GBM cells were treated with NHE1 inhibitor Cariporide, respectively. The cells were treated with acetoxymethyl ester of 2’,7’-Bis (2-carboxyethyl)-5(6)-carboxyfluorescein fluorescent probe and the fluorescence intensities at 440 nm and 490 nm were detected by ultraviolet spectrophotometer. The fluorescence intensity ratio was calculated to reflect NHE1 activity. The proliferative activity was detected by MTT and the invasion ability was detected by matrigel-Transwell assay.

The NHE1 activity, proliferation and invasion abilities of AM38 cells were all significantly higher than those of U251 cells (P=0.006, 0.010, 0.047, respectively). The NHE1 activity, proliferation and invasion abilities of both Cariporide-treated U251 and Cariporide-treated AM38 cells were all markedly decreased compared with those of DMSO-treated U251 and DMSO-treated AM38 cells, respectively (U251: P=0.012, 0.023, 0.044, respectively; AM38: P=0.006, 0.001, 0.038, respectively).

Cariporide could effectively inhibit the proliferation and invasion abilities of BRAF^WT and BRAF^V600E mutation type GBM cells.